24 research outputs found
Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization
Streptococcus pneumoniae (Spn) is a common cause of respiratory infection, but also frequently colonizes the nasopharynx in the absence of disease. We used mass cytometry to study immune cells from nasal biopsy samples collected following experimental human pneumococcal challenge in order to identify immunological mechanisms of control of Spn colonization. Using 37 markers, we characterized 293 nasal immune cell clusters, of which 7 were associated with Spn colonization. B cell and CD8+CD161+ T cell clusters were significantly lower in colonized than in non-colonized subjects. By following a second cohort before and after pneumococcal challenge we observed that B cells were depleted from the nasal mucosa upon Spn colonization. This associated with an expansion of Spn polysaccharide-specific and total plasmablasts in blood. Moreover, increased responses of blood mucosal associated invariant T (MAIT) cells against in vitro stimulation with pneumococcus prior to challenge associated with protection against establishment of Spn colonization and with increased mucosal MAIT cell populations. These results implicate MAIT cells in the protection against pneumococcal colonization and demonstrate that colonization affects mucosal and circulating B cell population
Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor
The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.<br>O objetivo neste estudo foi caracterizar o desenvolvimento subcutâneo do tumor de Walker 256 (W256) AR, uma variante regressiva do tumor de W256 A de rato. Ratos Wistar foram injetados com 4x10(6) células tumorais de W256 A ou W256 AR. O desenvolvimento tumoral foi avaliado diariamente. Nenhum dos tumores W256 A (n=20) regrediu, mas 62% dos ratos com tumor W256 AR apresentaram regressão completa dos tumores em até 35 dias. O crescimento contínuo dos tumores AR foi caracterizado pelo aumento da taxa de crescimento tumoral a partir do dia 12, alcançando valores maiores que 1,0g/dia, que foram significativamente superiores (p<0,05) aos valores de taxa de crescimento dos tumores regressivos AR. A imunossupressão por irradiação precedendo a injeção das células tumorais AR eliminou completamente a regressão tumoral e favoreceu disseminação metastática severa. Este estudo caracterizou o desenvolvimento do tumor de W256 AR em condições específicas, documentando a regressão espontânea deste tumor após a injeção subcutânea de altas doses de células tumorais em ratos Wistar. A avaliação diária da taxa de crescimento tumoral permite discriminar precocemente os tumores com crescimento continuo daqueles que são regressivos. A taxa de crescimento tumoral é um parâmetro útil para a avaliação dos animais experimentais, particularmente no período que precede a regressão dos tumores
Nasal pneumococcal density is associated with microaspiration and heightened human alveolar macrophage responsiveness to bacterial pathogens
Rationale: Pneumococcal pneumonia remains a global health
problem. Colonization of the nasopharynx with Streptococcus
pneumoniae (Spn), although a prerequisite of infection, is the main
source of exposure and immunological boosting in children and
adults. However, our knowledge of how nasal colonization impacts
on the lung cells, especially on the predominant alveolar macrophage
(AM) population, is limited.
Objectives: Using a controlled human infection model to achieve
nasal colonization with 6B serotype, we investigated the effect of Spn
colonization on lung cells.
Methods: We collected BAL from healthy pneumococcal challenged
participants aged 18\u201349 years. Confocal microscopy and
molecular and classical microbiology were used to investigate
microaspiration and pneumococcal presence in the lower airways.
AM opsonophagocytic capacity was assessed by functional assays
in vitro, whereas flow cytometry and transcriptomic analysis were
used to assess further changes on the lung cellular populations.
Measurements and Main Results: AMs from Spn-colonized
individuals exhibited increased opsonophagocytosis to
pneumococcus (11.4% median increase) for approximately 3
months after experimental pneumococcal colonization. AMs also
had increased responses against other bacterial pathogens.
Pneumococcal DNA detected in the BAL samples of Spn-colonized
individuals were positively correlated with nasal
pneumococcal density (r = 0.71; P = 0.029). Similarly, AM-heightened
opsonophagocytic capacity was correlated with
nasopharyngeal pneumococcal density (r = 0.61, P = 0.025).
Conclusions: Our findings demonstrate that nasal colonization
with pneumococcus and microaspiration prime AMs, leading to
brisker responsiveness to both pneumococcus and unrelated
bacterial pathogens. The relative abundance of AMs in the alveolar
spaces, alongside their potential for nonspecific protection, render
them an attractive target for novel vaccines
Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization
Host-parasite interactio
Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine
<div><p>Cervical cancer is a common type of cancer among women worldwide and infection with high-risk human papillomavirus (HPVs) types represents the major risk factor for the etiopathogenesis of the disease. HPV-16 is the most frequently identified HPV type in cervical lesions and expression of E6 and E7 oncoproteins is required for the uncontrolled cellular proliferation. In the present study we report the design and experimental testing of a recombinant multi-epitope protein containing immunogenic epitopes of HPV-16 E6 and E7. Tumor preventive assays, based on the engraftment of TC-1 cells in mice, showed that the E6E7 multi-epitope protein induced a full preventive anti-tumor protection in wild-type mice, as well as in mice deficient in expression of CD4<sup>+</sup> T cells and TLR4 receptor. Nonetheless, no anti-tumor protection was observed in mice deficient in CD8<sup>+</sup> T cells. Also, the vaccine promoted high activation of E6/E7-specific T cells and in a therapeutic-approach, E6E7 protein conferred full anti-tumor protection in mice. These results show a potential use of this E6E7 multi-epitope antigen as a new and promising antigen for the development of a therapeutic vaccine against tumors induced by HPV.</p></div
Recommended from our members
Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19
Young adults infected with SARS-CoV-2 are frequently asymptomatic or develop only mild disease. Because capturing representative mild and asymptomatic cases require active surveillance, they are less characterized than moderate or severe cases of COVID-19. However, a better understanding of SARS-CoV-2 asymptomatic infections might shed light into the immune mechanisms associated with the control of symptoms and protection. To this aim, we have determined the temporal dynamics of the humoral immune response, as well as the serum inflammatory profile, of mild and asymptomatic SARS-CoV-2 infections in a cohort of 172 initially seronegative prospectively studied United States Marine recruits, 149 of whom were subsequently found to be SARS-CoV-2 infected. The participants had blood samples taken, symptoms surveyed and PCR tests for SARS-CoV-2 performed periodically for up to 105 days. We found similar dynamics in the profiles of viral load and in the generation of specific antibody responses in asymptomatic and mild symptomatic participants. A proteomic analysis using an inflammatory panel including 92 analytes revealed a pattern of three temporal waves of inflammatory and immunoregulatory mediators, and a return to baseline for most of the inflammatory markers by 35 days post-infection. We found that 23 analytes were significantly higher in those participants that reported symptoms at the time of the first positive SARS-CoV-2 PCR compared with asymptomatic participants, including mostly chemokines and cytokines associated with inflammatory response or immune activation (i.e., TNF-α, TNF-β, CXCL10, IL-8). Notably, we detected 7 analytes (IL-17C, MMP-10, FGF-19, FGF-21, FGF-23, CXCL5 and CCL23) that were higher in asymptomatic participants than in participants with symptoms; these are known to be involved in tissue repair and may be related to the control of symptoms. Overall, we found a serum proteomic signature that differentiates asymptomatic and mild symptomatic infections in young adults, including potential targets for developing new therapies and prognostic tests
Anti-tumor responses elicited in mice immunized with E6E7 multi-epitope protein.
<p>Mice were immunized with three doses of PBS/2M urea (PBS) or E6E7 in intervals of 14 days. Mice were challenged with TC-1 tumor cells two weeks after the last dose. (A) Groups of five C57BL/6 mice were immunized as described. (B) TLR4 KO mice (C57BL10/ScCr) were vaccinated with PBS/2M urea (5 mice, PBS) or E6E7 (6 mice). (C) Groups of eight CD4 KO mice were vaccinated with PBS/2M urea (PBS) or E6E7. (D) Groups of five CD8 KO mice were vaccinated with PBS/2M urea (PBS) or E6E7. In parallel, C57BL/6 wild-type mice (5 mice) were used as a control of tumor growth competence. Asterisk indicates statistically significant percentage of tumor-free animals when compared to control group (** p < 0.005).</p